Method for promoting bone formation

Details Method for promoting bone formation Method for promoting bone formation

2007-05-22

2007-05-22

Hartley, Michael G. (Department: 1618)

Drug, bio-affecting and body treating compositions

Solid synthetic organic polymer as designated organic active...

Ion exchange resin

C424S078080, C424S078100, C424S078110, C424S078310

Reexamination Certificate

active

10686808

ABSTRACT:
Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename Renagel®, is the preferred polymer used in the invention.

REFERENCES:
patent: 5487888 (1996-01-01), Mandeville, III et al.
patent: 5496545 (1996-03-01), Holmes-Farley et al.
patent: 5607669 (1997-03-01), Mandeville, III et al.
patent: 5618530 (1997-04-01), Mandeville, III et al.
patent: 5624963 (1997-04-01), Mandeville, III et al.
patent: 5667775 (1997-09-01), Holmes-Farley et al.
patent: 5679717 (1997-10-01), Mandeville, III et al.
patent: 5693675 (1997-12-01), Mandeville, III et al.
patent: 5702696 (1997-12-01), Mandeville, III et al.
patent: 5703188 (1997-12-01), Mandeville, III et al.
patent: 5837674 (1998-11-01), Kumagai et al.
patent: 5900475 (1999-05-01), Mandeville, III et al.
patent: 5925379 (1999-07-01), Mandeville, III et al.
patent: 6083495 (2000-07-01), Holmes-Farley et al.
patent: 6083497 (2000-07-01), Huval et al.
patent: 6177478 (2001-01-01), Holmes-Farley et al.
patent: 6203785 (2001-03-01), Holmes-Farley et al.
patent: 6423754 (2002-07-01), Holmes-Farley et al.
patent: 6458889 (2002-10-01), Trollsas et al.
patent: 6509013 (2003-01-01), Holmes-Farley et al.
patent: 6556407 (2003-04-01), Brando et al.
patent: 6566407 (2003-05-01), Holmes-Farley et al.
patent: 6726905 (2004-04-01), Mandeville, III et al.
patent: 6733780 (2004-05-01), Tyler et al.
patent: 2002/0051822 (2002-05-01), Atherton et al.
patent: 2002/0159968 (2002-10-01), Petersen et al.
patent: 2002/0168333 (2002-11-01), Burke
patent: 2002/0182168 (2002-12-01), Holmes-Farley et al.
patent: 2002/0187120 (2002-12-01), Holmes-Farley et al.
patent: 2002/0187121 (2002-12-01), Burke
patent: 2003/0039627 (2003-02-01), Holmes-Farley et al.
patent: 2003/0049226 (2003-03-01), Burke et al.
patent: 2003/0086898 (2003-05-01), Holmes-Farley et al.
patent: 2003/0133902 (2003-07-01), Holmes-Farley et al.
patent: 2003/0224501 (2003-12-01), Young et al.
patent: WO 93/04373 (1993-03-01), None
patent: WO 98/42355 (1998-10-01), None
patent: WO 03/057225 (2003-07-01), None
Moe, S., et al., “Sevelamer HCL Improves Parathyroid Hormone (PTH) and Bone Function in Peritoneal Dialysis (PD) Patients with Probable Low Turnover Bone Disease,”American J. of Kidney Diseases, 37(4): A25 (abstract only-Tenth Annual Clinical Nephrology Meeting Abstracts), (2001).
Raggi, P., et al., “Sevelamer Preserves and Calcium Reduces Trabecular Bone Mineral Density,”J. American Society of Nephrology, 14: 502A (abstract only), (2003).
Katsumata, K., et al., “Sevelamer Hydrochloride Prevents Ectopic Calcification and Renal Osteodystrophy in Chronic Renal Failure Rats,”Kidney International, 64: 441-450 (2003).
Slatopolsky, E.A., et al., “RenaGel®, a Nonabsorbed Calcium- and Aluminum-Free Phosphate Binder, Lowers Serum Phosphorus and Parathyroid Hormone,”Kidney International, 55: 299-307 (1999).
Chertow, G.M., et al., “Sevelamer With and Without Calcium and Vitamin D: Observations From a Long-Term Open-Label Clinical Trial,”J. Of Renal Nutrition, 10(3): 125-132 (2000).
Chertow, G.M., et al., “Hyperparathyroidisnm and Dialysis Vintage,”Clinical Nephrology, 54(4): 295-300 (2000).
Malluche, H.H., and Mawad, H., “Management of Hyperphosphataemia of Chronic Kidney Disease: Lessons From the Past and Future Directions,”Nephrol. Dial. Transplant., 17: 1170-1175 (2002).
Cannata-Andia, J.B., and Rodriguez-Garcia, M., “Hyperphosphataemia as a Cardiovascular Risk Factor -How to Manage the Problem,”Nephrol. Dial. Transplant., 17(Suppl. 11): 16-19 (2002).
Nolan, C.R., and Qunibi, W.Y., “Calcium Salts in the Treatment of Hyperphosphatemia in Hemodialysis Patients,”Current Opinion in Nephrology and Hypertension, 12: 373-379 (2003).
{hacek over (C)}i{hacek over (z)}man, B., “Hyperphosphataemia and Treatment With Sevelamer in Haemodialysis Patients,”Nephrol. Dial. Transplant., 18(Suppl. 5): v47-v49 (2003).
Coco, M., and Rush, H., “Increased Incidence of Hip Fractures in Dialysis Patients With Low Serum Parathyroid Hormone,”Am. J. Kidney Diseases, 36(6): 1115-1121 (2000).
Taal, M.W., et al., “Risk Factors for Reduced Bone Density in Haemodialysis Patients,”Nephrol. Dial. Transplant., 14: 1922-1928 (1999).
Taal, M.W., et al., “Total Hip Bone Mass Predicts Survival in Chronic Hemodialysis Patients,”Kidney International, 63: 1116-1120 (2003).
Braun, J., et al., “Electron Beam Computed Tomography in the Evaluation of Cardiac Calcifications in Chronic Dialysis Patients,”American J. Kidney Diseases, 27(3): 394-401 (1996).
Cozzolino, M., et al., “Role of Calcium-Phosphate and Bone-Associated Proteins on Vascular Calcification in Renal Failure,”J. Am. Soc. Nephrol., 12: 2511-2516 (2001).
Loghman-Adham, M., “Phosphate Binders for Control of Phosphate Retention in Chronic Renal Failure,”Pediatr. Nephrol., 13: 701-708 (1999).
Elder, G., “Pathophysiology and Recent Advances in the Management of Renal Osteodystrophy,”J. Bone and Mineral Research, 17(12): 2094-2105 (2002).
Bardin, T., “Musculoskeletal Manifestations of Chronic Renal Failure,”Curr. Opin. Rheumatol., 15: 48-54 (2003).
Albaaj, F., and Hutchison, A.J., “Hyperphosphataemia in Renal Failure (Causes, Consequences and Current Management),”Drugs, 63(6): 577-596 (2003).
Martin, C.J., and Reams, S.M., “The Renal Dietitians's Role in Managing Hyperphosphatemia and Secondary Hyperparathyroidism in Dialysis Patients: A National Survey,”J. Renal Nutrition, 13(2): 133-136 (2003).
Fontaine, M.A., et al., “Fracture and Bone Mineral Density in Hemodialysis Patients,”Clinical Nephrol., 54(3): 218-226 (2000).
Kleinpeter, M.A., “Spectrum of Complications Related to Secondary Hyperparathyroidism in a Peritoneal Dialysis Patients,”Advances in Peritoneal Dialysis, 16: 286-290 (2000).
Chertow, G.M., et al., “Poly(allylamine hydrochloride) (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure,”Am. J. Kid. Dis., 29: 66-71 (1997).
Goldberg, D.I., et al., “Effect of RenaGel, an non-absorbed, calcium-and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients,”Nephrol. Dial. Transplant., 13: 2303-2310 (1998).
Chertow, G.M., et al., “A randomized trial of sevelamer hydrochloride (RenaGel®) with and without supplemental calcium. Strategies for the control of hyperphosphatemia in hemodialysis patients,”Clin. Nephrol., 51: 18-26 (1999).
Bleyer, A.J., et al., “A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients,”Am. J. Kid. Dis., 33: 694-701 (1999).
Chertow, G.M.,et al., “Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and lipid profile of haemodialysis patients,”Nephol. Dial. Transplant., 14: 2907-2914 (1999).
Chertow, G.M., et al., “Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients,”Kidney Int., 62: 245-252 (2002).
Chertow, G.M., Burke, S.K., Lazarus, J.M., Stenzel, K.HL, Wombolt, D., Goldberg, D., Boventre, J.V., and Slatopolsky, E., “Poly(allylamine hydrochloride) (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure”, Am. J. Kid. Dis. 29: 66-71 (1997).
Goldberg, D.I., Dillon, M.S., Slatopolsky, E.A. Garrett, B., Gray, J.R., Marbury, T., Weinberg, M., Wombolt, D., and Burke, S.K., “Effect of RenaGel, a non-absorbed, calcium-and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid

Affiliated with

Also associated with

Rating

Method for promoting bone formation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for promoting bone formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for promoting bone formation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3818217